ReviewTheScientificWorldJournal2010
New therapeutic targets for mood disorders.
Review in TheScientificWorldJournal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Unveiling Palmitoyl Thymidine Derivatives as Antimicrobial/Antiviral Inhibitors: Synthesis, Molecular Docking, Dynamic Simulations, ADMET, and Assessment of Protein-Ligand Interactions.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Anti-Inflammatory Effects of GPR55 Agonists and Antagonists in LPS-Treated BV2 Microglial Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Machine learning identifies fatigue as a key symptom of fibromyalgia reflected in tyrosine, purine, pyrimidine, and glutaminergic metabolism.Clinical and translational science · 2024Article
- The Use of Tamoxifen as a Potential Treatment for Bipolar Disorder.Psychiatry and clinical psychopharmacology · 2021Article
- In silico DFT study, molecular docking, and ADMET predictions of cytidine analogs with antimicrobial and anticancer properties.In silico pharmacology · 2021Article
- Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers.Psychopharmacology · 2018Article
- Identification of ENTPD8 and cytidine in pancreatic cancer by metabolomic and transcriptomic conjoint analysis.Cancer science · 2018Article
- Regulation of Glycogen Content in Astrocytes via Cav-1/PTEN/AKT/GSK-3β Pathway by Three Anti-bipolar Drugs.Neurochemical research · 2018Article
- Behavioral changes induced through adenosine A2A receptor ligands in a rat depression model induced by olfactory bulbectomy.Brain and behavior · 2018Article
- GSK3 activity regulates rhythms in hippocampal clock gene expression and synaptic plasticity.Hippocampus · 2017Article
- Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.Metabolic brain disease · 2016Article
- 7-Chlorokynurenic acid (7-CTKA) produces rapid antidepressant-like effects: through regulating hippocampal microRNA expressions involved in TrkB-ERK/Akt signaling pathways in mice exposed to chronic unpredictable mild stress.Psychopharmacology · 2015Article
- Translational Research in Bipolar Disorders.Neural plasticity · 2015Article
- Circulating microRNA-144-5p is associated with depressive disorders.Clinical epigenetics · 2015Article
- Time-dependent activation of MAPK/Erk1/2 and Akt/GSK3 cascades: modulation by agomelatine.BMC neuroscience · 2014Article
- Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications.Dialogues in clinical neuroscience · 2014Review
- Tamoxifen use for the management of mania: a review of current preclinical evidence.Psychopharmacology · 2014Review
- The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p.Cellular and molecular neurobiology · 2014Review
- New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- MicroRNAs: fundamental regulators of gene expression in major affective disorders and suicidal behavior?Frontiers in cellular neuroscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Existing pharmacological treatments for bipolar disorder (BPD) and major depressive disorder (MDD) are often insufficient for many patients. Here we describe a number of targets/compounds that clinical and preclinical studies suggest could result in putative novel treatments for mood disorders. These include: (1) glycogen synthase kinase-3 (GSK-3) and protein kinase C (PKC), (2) the purinergic system, (3) histone deacetylases (HDACs), (4) the melatonergic system, (5) the tachykinin neuropeptides system, (6) the glutamatergic system, and (7) oxidative stress and bioenergetics. The paper reviews data on new compounds that have shown antimanic or antidepressant effects in subjects with mood disorders, or similar effects in preclinical animal models. Overall, an improved understanding of the neurobiological underpinnings of mood disorders is critical in order to develop targeted treatments that are more effective, act more rapidly, and are better tolerated than currently available therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.